Topiramato, a new anti-epileptic drug;Topiramato, un nuevo antiepileptico

Revista de Neurologia

Volumn 25, Issue 144, 1997, Pages 1221-1225

  Herranz, J L ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Anti epileptic drugs; Epilepsy; Topiramato

Indexed keywords

TOPIRAMATE; ANTICONVULSIVE AGENT; DRUG DERIVATIVE; FRUCTOSE;

ANTICONVULSANT THERAPY; ARTICLE; DRUG EFFICACY; DRUG TOLERANCE; EPILEPSY; HUMAN; REVIEW;

ANTICONVULSANTS; EPILEPSY; FRUCTOSE; HUMANS;

EID: 0031204897     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Herranz JL. Ventajas e inconvenientes de los nuevos antiepilépticos. Rev Neurol 1996; 24: 1426-34.
2. Brown SD, Wolf HH, Swinyard EA, et al. The novel anticonvulsant topiramate enhances GABA-mediated chlorid flux. Epilepsia 1993; 34 (Suppl 2): S122-S23.
3. Coulter DA, Sombati S, de Lorenzo RJ. Selective effects of topiramate on sustained firing and spontaneous bursting in cultured hippocampal neurons. Epilepsia 1993; 34 (Suppl 2): S123.
4. Avoli M, Kawasaki H, Zona C. Effects induced by topiramate on sodium electrogenesis in mammaliam central neurons. Epilepsia 1996; 37 (Suppl 4): S51-2.
5. Armijo JA. Mecanismos moleculares de la epileptogénesis. En López de Munain A, Martí Massó JF, eds. Avances en neurociencias: epilepsia. San Sebastián: Editorial Fundación Illundain, 1994. p. 21-35.
6. Shank RP, Gardocki JF, Vaught JL, et al. Topiramate: preclinical evaluation of a structurally novel anticonvulsant. Epilepsia 1994; 35: 450-60.
7. Doose DR, Walker SA, Gisclon LG, Nayak RK. Single-dose pharmacokinetics and effect of food in the bioavailability of topiramate, a novel antiepileptic drug. J Clin Pharmacol 1996; 36: 884-91.
8. Perucca E. Pharmacokinetic profile of topiramate in comparison with other new antiepileptic drugs. Epilepsia 1996; 37 (Suppl 2): S8-S13.
9. Elwes RDC, Binnie CD. Clinical pharmacokinetics of newer antiepileptic drugs. Lamotrigine, vigabatrin, gabapentin and oxcarbazepine. Clin Pharmacokinet 1996; 30: 403-15.
10. Rambeck B, Specht U, Wolf P. Pharmacokinetic interactions of the new antiepileptic drugs. Clin Pharmacokinet 1996; 31: 309-24.
11. Bourgeois BFD. Drug interaction profile of topiramate. Epilepsia 1996; 37 (Suppl2): S14-7.
12. Reife R, Pledger G, Lim P, Karim R. Topiramate: pooled analysis of six placebo-controlled trials. Epilepsia 1996; 37 (Suppl 4): S74.
13. Ben-Menachem EW, Henriksen O, Dam M, et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 1996; 37: 539-43.
14. Privitera M, Fincham R, Penry J, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600,800, and 1.000 mg daily dosages. Neurology 1996; 46: 1678-83.
15. Sharief M, Viteri C, Ben-Menachem E, et al. Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Res 1996; 25: 217-24.
16. Chauvel P. Clinical efficacy in partial seizures adjunctive therapy and conversion to monotherapy. En Topiramate. Closing the therapeutic gap in epilepsy. Janssen-Cilag; 1996. p. 4-5.
17. Ben Menachem E. Preliminary results in primary generalized seizures. En Topiramate. Closing the therapeutic gap in epilepsy. Janssen-Cilag; 1996. p. 7.
18. Glauser TA. Experience in pediatric epilepsy and Lennox-Gastaut syndrome. En Topiramate. Closing the therapeutic gap in epilepsy. Janssen-Cilag; 1996. p. 8-9.
19. Espe-Lillo J, Ritter FJ, Frost MD, Spiegel RH, Reife R. Topiramate in childhood epilepsy: titration, adverse events, and efficacy in multiple seizure types. Epilepsia 1995; 36 (Suppl 4): S56.
20. Sachdeo R, Kugler S, Wenger E, Mandelbaum D. Topiramate in Lennox-Gastaut syndrome. Epilepsia 1996; 37 (Suppl 4): S118.
21. Herranz JL, Arteaga R, de las Cuevas I, Polo R. Eficacia y tolerabilidad del topiramato en 13 niños con síndrome de Lennox-Gastaut. Rev Neurol 1997; 25: 396.
22. Betts T, Smith K. Audit of clinical experience with the new antiepileptic drug topiramate. Epilepsia 1996; 37 (Suppl 4): S40.
23. Shorvon AD. Safety of topiramate: adverse events and relationships to dosing. Epilepsia 1996; 37 (Suppl 2): S18-S22.